Despite promising progress in malaria vaccine development in recent years, an efficacious subunit vaccine againstPlasmodium falciparumremains to be licensed and deployed. Cell-mediated protection from liver-stage malaria relies on a sufficient number of antigen-specific T cells reaching the liver during the time that parasites are present. A single vaccine expressing two antigens could potentially increase both the size and breadth of the antigen-specific response while halving vaccine production costs.
Journal article
American Society for Microbiology
2020-01-22T00:00:00+00:00
88